Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience

被引:28
作者
Mozas, Pablo [1 ]
Nadeu, Ferran [2 ,3 ]
Rivas-Delgado, Alfredo [1 ]
Rivero, Andrea [1 ]
Garrote, Marta [1 ]
Balague, Olga [2 ,4 ]
Gonzalez-Farre, Blanca [2 ,4 ]
Veloza, Luis [4 ]
Baumann, Tycho [1 ]
Gine, Eva [1 ,2 ,3 ]
Delgado, Julio [1 ,2 ,3 ]
Villamor, Neus [2 ,4 ]
Campo, Elias [2 ,3 ,4 ,5 ]
Magnano, Laura [2 ,3 ,4 ]
Lopez-Guillermo, Armando [1 ,2 ,3 ,5 ]
机构
[1] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
[2] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
[3] Ctr Invest Biomed Red Canc CIBERONC, Barcelona, Spain
[4] Hosp Clin Barcelona, Dept Pathol, Hematopathol Unit, Barcelona, Spain
[5] Univ Barcelona, Barcelona, Spain
关键词
IMPROVED SURVIVAL; NATURAL-HISTORY; RITUXIMAB; RISK; CYCLOPHOSPHAMIDE; TRANSFORMATION; CHEMOTHERAPY; VINCRISTINE; INTERFERON; PREDNISONE;
D O I
10.1038/s41408-020-0299-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although the introduction of immunotherapy has improved outcomes for follicular lymphoma (FL) patients, histological transformation (HT) and early relapse still confer a poor prognosis. We sought to describe the patterns of change in treatment, response, and outcome of FL patients at our institution over the last four decades. Seven hundred and twenty-seven patients (389 F/338 M; median age, 57 years) consecutively diagnosed with grade 1-3a FL between 1980 and 2017, categorized into four decades according to the time of diagnosis, constituted the study population. Clinical characteristics, treatment, response, absolute and relative survival, HT, second malignancies (SM), and causes of death were assessed. Median OS for the entire cohort was 17.6 years. From decade 1 to 4, there was an increase in the complete response rate (48 to 70%), progression-free survival (40 to 56% at 5 years), OS (77 to 86% at 5 years), and relative survival ratio (0.83 to 0.94 at 5 years), with no significant differences in the risk of HT or SM. Lymphoma remained the most common cause of death in all four decades. These findings illustrate the overall improvement in outcome for FL patients, but support the need for further research into risk stratification and management.
引用
收藏
页数:9
相关论文
共 25 条
[1]   Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group [J].
Alonso-Alvarez, Sara ;
Magnano, Laura ;
Alco-Ceba, Miguel ;
Andrade-Campos, Marcio ;
Espinosa-Lara, Natalia ;
Rodriguez, Guillermo ;
Mercadal, Santiago ;
Carro, Itziar ;
Sancho, Juan M. ;
Moreno, Miriam ;
Salar, Antonio ;
Garcia-Pallarols, Francesc ;
Arranz, Reyes ;
Cannata, Jimena ;
Terol, Maria Jose ;
Teruel, Ana I. ;
Rodriguez, Antonia ;
Jimenez-Ubieto, Ana ;
Gonzalez de Villambrosia, Sonia ;
Bello, Jose L. ;
Lopez, Lourdes ;
Monsalvo, Silvia ;
Novelli, Silvana ;
de Cabo, Erik ;
Infante, Maria S. ;
Pardal, Emilia ;
Garcia-Alvarez, Maria ;
Delgado, Julio ;
Gonzalez, Marcos ;
Martin, Alejandro ;
Lopez-Guillermo, Armando ;
Caballero, Maria D. .
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (05) :699-708
[2]   Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study [J].
Bachy, Emmanuel ;
Seymour, John F. ;
Feugier, Pierre ;
Offner, Fritz ;
Lopez-Guillermo, Armando ;
Belada, David ;
Xerri, Luc ;
Catalano, John V. ;
Brice, Pauline ;
Lemonnier, Francois ;
Martin, Alejandro ;
Casasnovas, Olivier ;
Pedersen, Lars M. ;
Dorvaux, Veronique ;
Simpson, David ;
Leppa, Sirpa ;
Gabarre, Jean ;
da Silva, Maria G. ;
Glaisner, Sylvie ;
Ysebaert, Loic ;
Vekhoff, Anne ;
Intragumtornchai, Tanin ;
Le Gouill, Steven ;
Lister, Andrew ;
Estell, Jane A. ;
Milone, Gustavo ;
Sonet, Anne ;
Farhi, Jonathan ;
Zeuner, Harald ;
Tilly, Herve ;
Salles, Gilles .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (31) :2815-+
[3]   Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe D'Etude des Lymphomes Folliculaires [J].
Brice, P ;
Bastion, Y ;
Lepage, E ;
Brousse, N ;
Haioun, C ;
Moreau, P ;
Straetmans, N ;
Tilly, H ;
Tabah, I ;
SolalCeligny, P .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :1110-1117
[4]   Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study [J].
Casulo, Carla ;
Byrtek, Michelle ;
Dawson, Keith L. ;
Zhou, Xiaolei ;
Farber, Charles M. ;
Flowers, Christopher R. ;
Hainsworth, John D. ;
Maurer, Matthew J. ;
Cerhan, James R. ;
Link, Brian K. ;
Zelenetz, Andrew D. ;
Friedberg, Jonathan W. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (23) :2516-U55
[5]  
Chan WC, 1997, BLOOD, V89, P3909
[6]   Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].
Cheson, Bruce D. ;
Fisher, Richard I. ;
Barrington, Sally F. ;
Cavalli, Franco ;
Schwartz, Lawrence H. ;
Zucca, Emanuele ;
Lister, T. Andrew .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+
[7]   Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis [J].
Federico, Massimo ;
Caballero Barrigon, Maria Dolores ;
Marcheselli, Luigi ;
Tarantino, Vittoria ;
Manni, Martina ;
Sarkozy, Clementine ;
Alonso-Alvarez, Sara ;
Wondergem, Marielle ;
Cartron, Guillaume ;
Lopez-Guillermo, Armando ;
Issa, Djamila ;
Morschhauser, Franck ;
Alcoceba, Miguel ;
Kimby, Eva ;
Rusconi, Chiara ;
Chamuleau, Martine ;
Holte, Harald ;
Lockmer, Sandra ;
Montoto, Silvia ;
da Silva, Maria Gomes ;
Aurer, Igor ;
Zucca, Emanuele ;
Paszkiewicz-Kozik, Ewa ;
Minoia, Carla ;
Skrypets, Tetiana ;
Blaker, Yngvild Nuvin ;
Salles, Gilles ;
Coiffier, Bertrand .
LANCET HAEMATOLOGY, 2018, 5 (08) :E359-E367
[8]   New treatment options have changed the survival of patients with follicular lymphoma [J].
Fisher, RI ;
LeBlanc, M ;
Press, OW ;
Maloney, DG ;
Unger, JM ;
Miller, TP .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8447-8452
[9]   A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].
GRAY, RJ .
ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154
[10]   Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma:: An East German Study Group hematology and oncology study [J].
Herold, Michael ;
Haas, Antje ;
Srock, Stefanie ;
Neser, Sabine ;
Al-Ali, Kathrin Haifa ;
Neubauer, Andreas ;
Doelken, Gottfried ;
Naumann, Ralph ;
Knauf, Wolfgang ;
Freund, Mathias ;
Rohrberg, Robert ;
Hoeffken, Klaus ;
Franke, Astrid ;
Ittel, Thomas ;
Kettner, Erika ;
Haak, Ursula ;
Mey, Ulrich ;
Klinkenstein, Christian ;
Assmann, Michael ;
von Gruenhagen, Ullrich .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1986-1992